RJA
MIRM icon

Raymond James & Associates’s Mirum Pharmaceuticals MIRM Stock Holding History

Raymond James & Associates’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$5.37M Sell
137,628
-6,586
-5% -$263K ﹤0.01% 1613
2024
Q2 		$4.93M Buy
144,214
+13,651
+10% +$358K ﹤0.01% 1585
2024
Q1 		$3.28M Sell
130,563
-5,119
-4% -$141K ﹤0.01% 1862
2023
Q4 		$4.01M Buy
135,682
+29,475
+28% +$892K ﹤0.01% 1681
2023
Q3 		$3.36M Buy
106,207
+38,619
+57% +$1.06M ﹤0.01% 1712
2023
Q2 		$1.75M Buy
67,588
+39,001
+136% +$1.04M ﹤0.01% 2145
2023
Q1 		$687K Buy
28,587
+8,834
+45% +$201K ﹤0.01% 2718
2022
Q4 		$385K Sell
19,753
-51,256
-72% -$1.01M ﹤0.01% 3064
2022
Q3 		$1.49M Buy
71,009
+25,439
+56% +$612K ﹤0.01% 2150
2022
Q2 		$887K Buy
45,570
+33,472
+277% +$789K ﹤0.01% 2527
2022
Q1 		$266K Sell
12,098
-6,555
-35% -$134K ﹤0.01% 3489
2021
Q4 		$298K Sell
18,653
-1,212
-6% -$18.9K ﹤0.01% 3444
2021
Q3 		$396K Buy
19,865
+5,991
+43% +$97.4K ﹤0.01% 3227
2021
Q2 		$240K Sell
13,874
-20,000
-59% -$358K ﹤0.01% 3580
2021
Q1 		$671K Buy
33,874
+541
+2% +$10.4K ﹤0.01% 2794
2020
Q4 		$582K Buy
+33,333
New +$655K ﹤0.01% 2707
2020
Q1 		– Sell
-8,843
Closed -$217K – 3634
2019
Q4 		$217K Buy
+8,843
New +$94.3K ﹤0.01% 3295

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Raymond James & Associates's MIRM Position: Q3 2024 in Review

Raymond James & Associates reduced its Mirum Pharmaceuticals (MIRM) stake by 4.6% in Q3 2024, selling an estimated $263K and leaving 137,628 shares worth $5.37M. The position accounts for ﹤0.01% of the portfolio, ranked #1613.

Raymond James & Associates first reported a position in MIRM in Q4 2019 and has held it in 17 quarters since. 178 funds tracked by Wall St. Rank hold MIRM as of Q3 2024.

  • Raymond James & Associates held 137,628 shares of Mirum Pharmaceuticals worth $5.37M as of Q3 2024.
  • Raymond James & Associates sold 6,586 Mirum Pharmaceuticals shares in Q3 2024, an estimated $263K.
  • Mirum Pharmaceuticals made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #1613 holding.
  • Raymond James & Associates first reported a position in Mirum Pharmaceuticals in Q4 2019 and has held it in 17 quarters since.
  • 178 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.